L-2-Hydroxyglutaric Aciduria (L2GA)

L-2-Hydroxyglutaric Aciduria

Overview

L-2-Hydroxyglutaric Aciduria is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Path: /diseases/l-2-hydroxyglutaric-aciduria

L-2-Hydroxyglutaric aciduria (L2GA) is a rare autosomal recessive neurometabolic disorder characterized by the accumulation of L-2-hydroxyglutaric acid in body fluids and tissues, particularly in the brain. The disease is caused by deficiency of L-2-hydroxyglutarate dehydrogenase (L2HGDH), an enzyme involved in the metabolism of L-2-hydroxyglutarate, a metabolite produced during normal cellular processes. This accumulation leads to progressive neurodegeneration, with clinical manifestations including cerebellar ataxia, intellectual disability, and characteristic MRI findings of leukoencephalopathy[@lhydroxyglutaric2020].

Genetics

L2HGDH Gene

L-2-hydroxyglutaric aciduria is caused by homozygous or compound heterozygous mutations in the L2HGDH gene (chromosome 14q22.1), which encodes the enzyme L-2-hydroxyglutarate dehydrogenase. This enzyme catalyzes the oxidation of L-2-hydroxyglutarate to 2-ketoglutarate (alpha-ketoglutarate) in the mitochondrial matrix, using FAD as a cofactor[@lhgdh2004].

Inheritance

L-2-Hydroxyglutaric Aciduria

Overview

L-2-Hydroxyglutaric Aciduria is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research.

Path: /diseases/l-2-hydroxyglutaric-aciduria

L-2-Hydroxyglutaric aciduria (L2GA) is a rare autosomal recessive neurometabolic disorder characterized by the accumulation of L-2-hydroxyglutaric acid in body fluids and tissues, particularly in the brain. The disease is caused by deficiency of L-2-hydroxyglutarate dehydrogenase (L2HGDH), an enzyme involved in the metabolism of L-2-hydroxyglutarate, a metabolite produced during normal cellular processes. This accumulation leads to progressive neurodegeneration, with clinical manifestations including cerebellar ataxia, intellectual disability, and characteristic MRI findings of leukoencephalopathy[@lhydroxyglutaric2020].

Genetics

L2HGDH Gene

L-2-hydroxyglutaric aciduria is caused by homozygous or compound heterozygous mutations in the L2HGDH gene (chromosome 14q22.1), which encodes the enzyme L-2-hydroxyglutarate dehydrogenase. This enzyme catalyzes the oxidation of L-2-hydroxyglutarate to 2-ketoglutarate (alpha-ketoglutarate) in the mitochondrial matrix, using FAD as a cofactor[@lhgdh2004].

Inheritance

L2GA follows an autosomal recessive inheritance pattern. Parents of an affected individual are typically asymptomatic carriers, with a 25% recurrence risk for subsequent pregnancies. The disease has been reported in various ethnic groups, with higher prevalence in populations with consanguinity.

Prevalence

L-2-hydroxyglutaric aciduria is an extremely rare disorder, with approximately 100 cases reported in the literature worldwide. The exact prevalence is unknown but estimated to be less than 1 per million population.

Pathophysiology

Metabolic Block

The primary metabolic defect in L2GA involves impairment of L-2-hydroxyglutarate dehydrogenase activity:

• Lysine degradation via the pipecolic acid pathway
• Hydroxylation of 2-ketoglutarate in a side reaction of various enzymes

• This reaction is part of the mitochondrial metabolic network
• 2-ketoglutarate enters the TCA cycle for further metabolism

• Accumulation of L-2-hydroxyglutarate in the brain and other tissues
• Elevated levels in cerebrospinal fluid, plasma, and urine
• Secondary effects on brain development and function[@biochemical2015]

Neurotoxicity

The mechanisms by which L-2-hydroxyglutarate accumulation causes neurodegeneration include:

• Oxidative stress: L-2-hydroxyglutarate can generate [reactive oxygen species](/entities/reactive-oxygen-species)
• Energy metabolism impairment: Secondary mitochondrial dysfunction
• Epigenetic effects: 2-ketoglutarate is a cofactor for DNA demethylases; accumulation of L-2-hydroxyglutarate may interfere with epigenetic regulation
• Excitotoxicity: Potential effects on glutamate signaling

Neuropathology

Postmortem studies show:

• Diffuse cerebral leukoencephalopathy
• Vacuolation of white matter
• Cerebellar atrophy, particularly of the dentate nucleus
• Variable neuronal loss
• Myelin abnormalities

Clinical Presentation

Age of Onset

Symptoms typically begin in early childhood, usually between ages 1-5 years, though milder forms may present later.

Core Clinical Features

Neurological Symptoms:

• Cerebellar ataxia: The most consistent feature, characterized by:
• Gait instability and truncal ataxia
• Limb incoordination
• Dysarthria (slurred speech)
• Nystagmus
• Cognitive impairment:
• Variable intellectual disability (mild to severe)
• Developmental delays
• Learning difficulties
• Movement disorders:
• Dystonia
• Chorea
• Tremor
• Myoclonus (in some cases)
• Seizures: Occur in approximately 30-50% of patients

• Macrocephaly (enlarged head circumference) in some patients
• Short stature may be present
• No significant organ involvement outside the nervous system

Disease Progression

L2GA is typically slowly progressive:

• Motor symptoms often worsen over years
• Cognitive decline may be gradual or stepwise
• Life expectancy varies; many patients survive into adulthood
• Some patients experience periods of acute regression, sometimes triggered by illness or metabolic stress[@clinical2019]

Diagnosis

Biochemical Testing

Urine Organic Acid Analysis:

• Elevated urinary excretion of L-2-hydroxyglutarate is the biochemical hallmark
• Levels are typically markedly elevated (10-100x normal)
• Analysis by GC-MS or LC-MS/MS is the standard method

• Elevated L-2-hydroxyglutarate in plasma
• Even higher levels in cerebrospinal fluid
• Normal levels of other organic acids help distinguish from related disorders

Neuroimaging

MRI Findings:

• Diffuse, symmetric cerebral leukoencephalopathy
• T2/FLAIR hyperintensities in the deep white matter
• Relative preservation of subcortical U-fibers early in disease
• Cerebellar involvement, particularly of the dentate nuclei
• Brainstem may be affected in advanced disease
• Progressive atrophy over time[@neuroimaging2018]

Genetic Testing

• Sequencing of the L2HGDH gene confirms the diagnosis
• Identifies pathogenic variants (missense, nonsense, splice-site, deletions)
• Carrier testing for at-risk family members
• Prenatal diagnosis possible for families with known mutations

Differential Diagnosis

L2GA must be distinguished from:

• D-2-hydroxyglutaric aciduria (caused by D2HGDH mutations; different clinical phenotype)
• Combined D,L-2-hydroxyglutaric aciduria (caused by SLC25A1 mutations)
• Other leukodystrophies (Metachromatic leukodystrophy, Krabbe disease)
• Cerebral palsy and other developmental disorders

Management

Current Treatment Approaches

There is no cure for L2GA. Treatment is supportive and focuses on symptom management:

Seizure Control:

• Standard antiepileptic medications
• Response varies among patients

• Dystonia: Baclofen, anticholinergics, botulinum toxin injections
• Tremor: Beta-blockers, primidone

• Physical therapy for gait training and spasticity management
• Occupational therapy for ADL training
• Speech therapy for dysarthria
• Educational support and special education services

• Regular monitoring of growth and nutritional status
• Dietitian consultation as needed

Experimental Approaches

Dietary Interventions:

• Some reports of benefit from dietary restriction of lysine (precursor to L-2-hydroxyglutarate)
• Carnitine supplementation has been tried

Gene Therapy: Under investigation in preclinical models

Prognosis

The prognosis for individuals with L2GA is variable:

• Early-onset severe form: Rapid progression in childhood
• Classic form: Slow progression over decades
• Mild/late-onset form: May have stable or slowly progressive disease

• Many patients survive into adulthood
• Severe cases may have shortened lifespan
• Quality of life can be significantly affected by motor and cognitive impairments

Research Directions

Current research areas include:

• Natural history studies to characterize disease progression
• Development of biomarkers for monitoring
• Gene therapy approaches using viral vectors
• Small molecule therapies targeting metabolic pathways
• Understanding genotype-phenotype correlations[@therapeutic2022]

See Also

• [Organic Acidemias](/diseases/organic-acidemias)
• [Leukoencephalopathy](/mechanisms/leukoencephalopathy)
• [Cerebellar Ataxia](/diseases/cerebellar-ataxia)
• [2-Ketoglutarate](/entities/2-ketoglutarate)
• [Mitochondrial Metabolism](/mechanisms/mitochondrial-metabolism)
• [Oxidative Stress](/mechanisms/oxidative-stress)

Recent Research (2024-2026)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References